

# CURRICULUM VITAE



## Diogo Jesus, MD

Consultant Rheumatologist  
Centro Hospitalar de Leiria, Portugal  
Email: jesus.p.diogo@gmail.com  
ORCID: 0000-0003-3136-0722

### CURRENT POSITIONS

- Consultant Rheumatologist, Centro Hospitalar de Leiria, Portugal
- PhD Candidate in Medicine, University of Beira Interior, Portugal

### EDUCATION & SPECIALIST TRAINING

- **PhD in Medicine (ongoing)**

Faculty of Health Sciences, University of Beira Interior, Portugal

*Thesis:* Development of improved outcome measures for SLE disease activity assessment

*Supervisors:* Prof. Luís Inês; Prof. Andrea Doria

- **Clinical Fellowship in SLE**

Azienda Ospedaliera di Padova, Padua, Italy

- **Specialist Training in Rheumatology**

Centro Hospitalar e Universitário de Coimbra, Portugal

- **MD, Medicine**

NOVA Medical School, Universidade Nova de Lisboa, Portugal

### SCIENTIFIC & ACADEMIC LEADERSHIP

- Responsible / Coordinator, **SLE Study Group**, Portuguese Society of Rheumatology
- Member, **Local Organizing Committee**, 15<sup>th</sup> European Lupus Meeting 2026
- Faculty Member, **EULAR Online Course on Systemic Lupus Erythematosus**
- Member, **Scientific Committee, Portuguese Congress of Rheumatology** (2025, 2026)

### SELECTED SCIENTIFIC PUBLICATIONS

*(Author of over 30 peer-reviewed publications in international journals. Full publication list available upon request)*

- **Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.** *Ann Rheum Dis.* 2019;78(3):365-371. Doi: 10.1136/annrheumdis-2018-214502.
- **Jesus D, Larosa M, Henriques C, et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.** *Ann Rheum Dis.* 2021;80(12):1568-1574. Doi: 10.1136/annrheumdis-2021-220363.
- **Jesus D, Henriques C, Matos A, et al. Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.** *Arthritis Care Res (Hoboken).* 2024 Jan 22. Doi: 10.1002/acr.25305.
- **Inês LS, Fredi M, Jesus D, Shumilova A, Franceschini F, Vital EM. What is the best instrument to measure disease activity in SLE? - SLE-DAS vs Easy BILAG.** *Autoimmun Rev.* 2024;23(1):103428. Doi: 10.1016/j.autrev.2023.103428.
- **Saraiva L, Cunha RN, Jesus D, Gatto M, Zen M, Iaccarino L, da Silva JAP, Doria A, Inês LS. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.** *Rheumatology (Oxford).* 2024;63(4):1123-1129. Doi: 10.1093/rheumatology/kead353
- **Jesus D, Henriques C, Matos A, et al. SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies.** *Lupus Sci Med.* 2025 May 16;12(1):e001499. Doi: 10.1136/lupus-2025-001499.

### PRESENTATIONS IN SCIENTIFIC MEETINGS

- **MAIN INTERNATIONAL PRESENTATIONS (SELECTED)**

Multiple oral and invited presentations at European Lupus Meetings and EULAR Congresses and European Summer School (2017-2024) focused on SLE disease activity, remission, low disease activity, flare definitions, and clinical trial outcomes.

### AWARDS (SELECTED)

- **Top 6 Clinical Abstracts**, EULAR Congress 2021
- **Best Oral Communication**, Portuguese Congress of Rheumatology (2019, 2017)
- **EULAR Scientific Training Bursary, 2017**

## MEMBERSHIP OF SCIENTIFIC SOCIETIES

- European Lupus Society (SLEuro)
- Portuguese Society of Rheumatology
- EMEUNET – Emerging EULAR Network

January, 2026

## **Motivation Letter**

### **Purpose: Candidacy for the SLEURO Executive Committee**

Dear Members of SLEuro,

I am writing to express my motivation to stand as a candidate for election to the SLEURO Executive Committee. As a clinician and researcher dedicated to SLE, I strongly align with SLEuro's mission to promote collaborative research, education, and excellence in lupus care, and I would be honoured to contribute more actively to this community.

I am a consultant rheumatologist with a focused clinical practice in SLE and sustained involvement in clinical and outcomes-based research. My academic work has centred on disease activity assessment, responder definitions, and treat-to-target strategies in SLE, using data from international cohorts and phase II and III clinical trials, with the aim of improving the clinical relevance and interpretability of research outcomes.

In parallel, I have been actively engaged in European and international collaborations, as well as in the coordination of structured SLE initiatives within a national rheumatology society. These roles have strengthened my experience in collaborative work, scientific coordination, and educational activities, and reinforced my belief in the value of consistent methodologies and shared goals across centres.

If elected, I would be particularly motivated to support collaborative research initiatives, promote harmonisation of outcome measures in SLE studies, and contribute to the engagement and development of early- and mid-career clinicians and researchers within the SLEuro network. I am also keen to help strengthen the translation of scientific advances into clinical practice and education.

I fully recognise that serving on the Executive Committee requires commitment, active participation, and teamwork. I approach this candidacy with a strong sense of service to the SLEuro community and a willingness to contribute constructively to its strategic objectives.

Thank you very much for considering my candidacy.

With kind regards,

**Diogo Jesus, MD, PhD Candidate**  
Consultant Rheumatologist

31 January 2026